SNSE (Sensei Biotherapeutics, Inc. Common Stock) Stock Analysis - News
Sensei Biotherapeutics, Inc. Common Stock (SNSE) is a publicly traded Healthcare sector company. As of May 21, 2026, SNSE trades at $17.58 with a market cap of $26.70M and a P/E ratio of -1.04. SNSE moved +4.59% today. Year to date, SNSE is +80.68%; over the trailing twelve months it is +167.91%. Its 52-week range spans $5.00 to $36.76. Rallies surfaces SNSE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in SNSE news today?
Sensei Biotherapeutics Completes $200M Financing and Narrows 2025 Net Loss to $21.1M: Sensei Biotherapeutics closed a $200 million private placement and acquired Faeth Therapeutics to support PIKTOR’s Phase 2 endometrial and planned Phase 1b breast cancer trials, expecting topline data by late 2026. Full-year 2025 cash fell to $21.2 million as net loss narrowed to $21.1 million from $30.2 million in 2024.
MILLENNIUM MANAGEMENT LLC bought 1.11K (~$36.99K) on Apr 7, 2026.
MILLENNIUM MANAGEMENT LLC sold 2.12K (~$61.21K) on Apr 7, 2026.
MILLENNIUM MANAGEMENT LLC sold 205 (~$6.09K) on Apr 7, 2026.
SNSE Analyst Consensus
SNSE analyst coverage data. Average price target: $0.00.
Common questions about SNSE
What changed in SNSE news today?
Sensei Biotherapeutics Completes $200M Financing and Narrows 2025 Net Loss to $21.1M: Sensei Biotherapeutics closed a $200 million private placement and acquired Faeth Therapeutics to support PIKTOR’s Phase 2 endometrial and planned Phase 1b breast cancer trials, expecting topline data by late 2026. Full-year 2025 cash fell to $21.2 million as net loss narrowed to $21.1 million from $30.2 million in 2024.
Does Rallies summarize SNSE news?
Yes. Rallies summarizes SNSE news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is SNSE research on Rallies investment advice?
No. Rallies provides research, data, and educational context for SNSE. It does not provide personalized investment advice.
